← Search & browse all drugs
BLOOD AND BLOOD FORMING ORGANS › ANTITHROMBOTIC AGENTS › ANTITHROMBOTIC AGENTS › Platelet aggregation inhibitors excl. heparin
iloprost
B01AC11
Forms & Strengths
- Inhalation solution: 10 mcg/mL (2 mL ampules)
Adult Dosing
- Pulmonary arterial hypertension: 2.5 mcg to 5 mcg per inhalation administered via Ventilis or I-neb AAD system, 6 to 9 times daily during waking hours
- Initial dose: 2.5 mcg; if tolerated, increase to 5 mcg
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Treatment of pulmonary arterial hypertension (WHO Group 1) in patients with NYHA Functional Class III or IV symptoms to improve exercise tolerance and symptoms
Mechanism of Action
- Synthetic analog of prostacyclin PGI2; dilates systemic and pulmonary arterial vascular beds and inhibits platelet aggregation
Contraindications
- Hypersensitivity to iloprost
- Pulmonary venous hypertension
- Active bleeding
- Conditions predisposing to bleeding (e.g., active peptic ulcer)
- Severe coronary heart disease or unstable angina
- Myocardial infarction within the last 6 months
- Decompensated heart failure without close medical supervision
- Arrhythmias associated with high risk of termination
Adverse Reactions
- Vasodilation (flushing)
- Increased cough
- Headache
- Trismus
- Hypotension
- Insomnia
- Nausea
- Syncope
- Flu-like symptoms
- Peripheral edema
Drug Interactions
- Antihypertensives and vasodilators: May increase the risk of systemic hypotension
- Anticoagulants, antiplatelet agents, NSAIDs: May increase the risk of bleeding due to additive antiplatelet effects
Curated Content: Needs Vetting Before Put to Clinical Use